We've got you covered
We are here to guide you in making tough decisions with your hard earned money. Drop us your details and we will reach you for a free one on one discussion with our experts.
or
Call us on: +917410000494
Ind-Swift Limited develops pharmaceutical formulations, finished goods dosages, active pharmaceutical ingredients, and herbal products in India. It offers medicines for various therapeutic segments, such as ENT, dentistry, anti-infective, cardio-diabetic, and orthopedic therapies under the Zoxiclav, Glypar, Olmiswif, Telhim, Ozodom-DSR, Cefextil-O, Swiclo-Sp, Swifix-O, Swifix 200, Stemin, and Stemin Forte names; gynecology, pediatrics, dermatology, and GP under the Anin, Suprox, Cozy, Distone, and Oliade name; and antibiotic, anti-cold, nutraceuticals, anti-diarrheal, anti-malarial, anti-depressants, cardiology, diabetology, neurology, and oncology. The company also provides contract research and manufacturing services. It serves government dispensaries, doctors, and hospitals through retailers, stockists, and carrying and forwarding channels. The company exports its products to approximately 50 countries. Ind-Swift Limited was founded in 1983 and is based in Chandigarh, India.
TODAY'S HIGH
9.6
TODAY'S LOW
9
52 WEEK HIGH
18.5
52 WEEK LOW
8.25
% of Shares Held by
All Insider
66.85%
% of Shares Held by
Institutions
0.00%
% of Float Held by
Institutions
0.00%
Number of Institutions
Holding Shares
0
MARKET CAP
51.30 Cr.
ETERPRISE VALUE
1065.68 Cr.
NO. OF SHARES
5.41 Cr.
BOOK VALUE
-138.125
DIV. YIELD
0.4%
DEBT
1029.53 Cr.
GROSS PROFIT
188.21 Cr.
CASH
13.83 Cr.
REVENUE
412.45 Cr.
REVENUE/SHARE
76.179
| Particulars | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|
| Investments | 0 | 1.60 Cr. | 1.60 Cr. | 1.60 Cr. |
| Change To Liabilities | 0 | 0 | 0 | 0 |
| Total cashflows from Investing Activities | -18.41 Cr. | -16.71 Cr. | -11.35 Cr. | -13.70 Cr. |
| Net Borrowings | -24.13 Cr. | -4.67 Lakhs | 5.94 Cr. | -9.78 Cr. |
| Total Cash from Financing Activities | -84.01 Cr. | -48.29 Cr. | -26.20 Cr. | -13.03 Cr. |
| Other Liabilities | 21.95 Cr. | 50.04 Cr. | 25.20 Cr. | 16.94 Cr. |
| Total Assets | 0 | 0 | 0 | 0 |
| Net Income | -20.02 Cr. | -29.81 Cr. | -19.12 Cr. | 8.19 Cr. |
| Change in Cash | -12.80 Cr. | 12.23 Cr. | -2.96 Cr. | 16.04 Cr. |
| Effect of Exchange Rate | 0 | 0 | 0 | 0 |
| Total Cash from Operating Activities | 89.62 Cr. | 77.24 Cr. | 34.59 Cr. | 42.78 Cr. |
| Depreciation | 32.07 Cr. | 30.70 Cr. | 33.59 Cr. | 33.97 Cr. |
| Other Cashflows from Investing Activities | 1.06 Cr. | 1.81 Cr. | 1.01 Cr. | 28.48 Lakhs |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Change to Inventory | -6.73 Cr. | -10.44 Cr. | -3.40 Cr. | -3.55 Cr. |
| Change to Account Receivables | 16.78 Cr. | -15.91 Cr. | -20.76 Cr. | -10.98 Lakhs |
| Other Cashflows from Financing Activities | -59.88 Cr. | -48.25 Cr. | -32.14 Cr. | -3.25 Cr. |
| Change to Net Income | 45.56 Cr. | 50.67 Cr. | 19.09 Cr. | -12.65 Cr. |
| Capital Expenditures | -19.57 Cr. | -20.21 Cr. | -12.63 Cr. | -14.02 Cr. |
| Particulars | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|
| Research Development | None | None | None | None |
| Effect of Accounting Charges | None | None | None | None |
| Income Before Tax | -19.60 Cr. | -29.49 Cr. | -16.66 Cr. | 8.19 Cr. |
| Minority Interest | None | None | None | None |
| Net Income | 13.27 Cr. | 14.25 Cr. | 2.77 Cr. | -16.57 Cr. |
| Selling General Administrative | 63.15 Cr. | 60.44 Cr. | 56.46 Cr. | 54.23 Cr. |
| Gross Profit | 186.69 Cr. | 170.93 Cr. | 146.31 Cr. | 131.21 Cr. |
| Ebit | 13.27 Cr. | 14.25 Cr. | 2.77 Cr. | -16.57 Cr. |
| Operating Income | 13.27 Cr. | 14.25 Cr. | 2.77 Cr. | -16.57 Cr. |
| Other Operating Expenses | 78.18 Cr. | 63.52 Cr. | 53.48 Cr. | 59.57 Cr. |
| Interest Expense | -57.15 Cr. | -51.45 Cr. | -34.66 Cr. | -3.47 Cr. |
| Extraordinary Items | None | None | None | None |
| Non Recurring | None | None | None | None |
| Other Items | None | None | None | None |
| Income Tax Expense | 41.79 Lakhs | 32.28 Lakhs | 2.46 Cr. | 0 |
| Total Revenue | 397.71 Cr. | 359.66 Cr. | 336.87 Cr. | 295.16 Cr. |
| Total Operating Expenses | 384.43 Cr. | 345.40 Cr. | 334.09 Cr. | 311.73 Cr. |
| Cost of Revenue | 211.02 Cr. | 188.73 Cr. | 190.55 Cr. | 163.95 Cr. |
| Total Other Income Expense Net | -32.87 Cr. | -43.75 Cr. | -19.43 Cr. | 24.76 Cr. |
| Discontinued Operations | None | None | None | None |
| Net Income from Continuous Ops. | -20.02 Cr. | -29.81 Cr. | -19.12 Cr. | 8.19 Cr. |
| Net Income Applicable to Common Shares | -20.02 Cr. | -29.81 Cr. | -19.12 Cr. | 8.19 Cr. |
| Particulars | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|
| Intangible Assets | 10.38 Cr. | 11.93 Cr. | 16.07 Cr. | 20.07 Cr. |
| Capital Surplus | 0 | 71.07 Cr. | 71.07 Cr. | 71.07 Cr. |
| Total Liabilities | 1352.07 Cr. | 1366.73 Cr. | 1314.76 Cr. | 1275.16 Cr. |
| Stock Holder Equity | -720.32 Cr. | -695.16 Cr. | -713.11 Cr. | -676.73 Cr. |
| Minority Interest | 0 | 0 | 0 | 0 |
| Other Liabilities | 85 Cr. | 82.34 Cr. | 41.16 Cr. | 40.13 Cr. |
| Total Assets | 631.75 Cr. | 671.57 Cr. | 601.64 Cr. | 598.42 Cr. |
| Common Stock | 10.83 Cr. | 10.83 Cr. | 10.83 Cr. | 10.83 Cr. |
| Retained Earnings | 0 | -807.66 Cr. | -777.85 Cr. | -758.73 Cr. |
| Other Liabilities | 15.19 Cr. | 16.21 Cr. | 16.24 Cr. | 14.62 Cr. |
| Good Will | 0 | 0 | 0 | 0 |
| Treasury Stock | -731.15 Cr. | 30.59 Cr. | -17.17 Cr. | 8.18 Lakhs |
| Other Assets | 80.45 Cr. | 147.46 Cr. | 99.88 Cr. | 110.42 Cr. |
| Cash | 16.18 Cr. | 28.99 Cr. | 16.75 Cr. | 19.72 Cr. |
| Current Liabilities | 717.59 Cr. | 706.16 Cr. | 654.12 Cr. | 615.86 Cr. |
| Long Term Asset Charges | 0 | 0 | 0 | 0 |
| Short Long Term Debt | 416.35 Cr. | 2.51 Cr. | 2.02 Cr. | 1.34 Cr. |
| Other Stockholder Equity | -731.15 Cr. | 30.59 Cr. | -17.17 Cr. | 8.18 Lakhs |
| Property Plant Equipment | 234.11 Cr. | 245.13 Cr. | 253.59 Cr. | 270.48 Cr. |
| Total Cur. Assets | 242.44 Cr. | 265.17 Cr. | 228.64 Cr. | 193.51 Cr. |
| Long Term Investments | 64.35 Cr. | 1.86 Cr. | 3.44 Cr. | 3.92 Cr. |
| Net Tangible Assets | -730.70 Cr. | -707.10 Cr. | -729.18 Cr. | -696.80 Cr. |
| Short Term Investments | 0 | 0 | 0 | 0 |
| Net Receivables | 90.62 Cr. | 107.94 Cr. | 94.16 Cr. | 75.56 Cr. |
| Long Term Debt | 619.29 Cr. | 644.16 Cr. | 644.21 Cr. | 644.67 Cr. |
| Inventory | 69.58 Cr. | 62.84 Cr. | 52.40 Cr. | 48.99 Cr. |
| Accounts Payable | 203.90 Cr. | 232.01 Cr. | 226.22 Cr. | 198.83 Cr. |
Open a demat account through us and get the account opening charges waived off
open paperless account